@BethIWallace on MACE risk with GC use in 26,239 veterans with RA. GC (>30 days in 6 months) associated 15% ⬆️in MACE. Abstr#1428 #ACR21 @RheumNow https://t.co/InXPiuO1GY

#ACR21 Abs#1428. Retrospective cohort VA study ▶️45% of patients got >30 days of GC use in a 6-month period - high # of pts! ▶️3% MACE events during study period ⭐️30 days of glucocorticoids = 15%⬆️ in odds of MACE in RA pts! @Rheumnow https://t.co/m5bl9Ho163 https://t.co/v8hdzi1Vrb

• https://bit.ly/3bPbT7t

Achieving MDA in PsA results in improvements in disease activity measures, PROMs and maintenance of therapy. It may help increased work productivity and reductions in lost wages in PsA @RheumNow #ACR21 Abst#1344 https://t.co/KR1DPXt7jh https://t.co/3bfeiXxN54

• Impact of Achieving Minimal Disease Activity on Patient-Reported Outcome Measur…

Multinational web survey (UPLIFT) showing patients with PsA➕ active PsO associated with - more active disease; 🔼prevalence comorbidities ; depression ⭐️Positive depression screen associated with overall disease impact as measured by PsAID Abst#1351 #ACR21 @RheumNow https://t.co/w1JETzNao9

#ACR21 #Abstr1425 Interim AURORA2 (Extension of original RCT to 2 years) showed #lupus nephritis patients on voclosporin maintained meaningful low uPCR and stability of eGFR at 2yrs. No unexpected safety signals @RheumNow https://t.co/aclJZNOGc5 https://t.co/ENl9SzMHN3

• https://bit.ly/3wrzq

How much PNL do you need with TCZ in GCA, to avoid early risks of visual loss? GiACTA: 26w. Can we do better? GUSTO: 3d pulse IVMP. Not enough. Is 8w the sweet spot?🤔 sustained remission off PNL at 52w: 20/27 no visual loss/ischaemia @MGHrheumatology #ACR21 ABST1413 @RheumNow https://t.co/IV9MorvTeW

#Voclosporin still going strong in LTE in #lupus nephritis AURORA 2. No new safety signals, stable GFR. Cost may be problem! Abst#1425 #ACR21 #ACRBest @RheumNow https://t.co/biEptZbJoz

#ACR21 Abs#1426 - VEXAS! Predictors of mortality: ▶️p.MetVal41 genotype (HR 3.5) ▶️Absence of ear chondritis (HR 3.8) ▶️Transfusion dependence (HR 2.6) @Rheumnow https://t.co/m5bl9Ho163 https://t.co/LSNcF6EZHv

• https://bit.ly/3bPbT7t

Abst1338 #acr21 @RheumNow BE ACTIVE Bimekizumab in 206 PsA: Over half of TNFi-n pts achieved ACR50 resolution of dactylitis (70.2% NRI; 100.0% OC) & enthesitis (60.7% NRI; 80.6% OC) PASI100 at Wks 48/152 63.3/58.7% Low serious infect, mild/moderate candida. 1 microscopic colitis https://t.co/CJXyywZYJd

Abstr 1044 Anastasiou & colleagues examined Rx of inappropriate medications in elderly patients with rheumatic disease (RD) - 40% RD patients received inappropriate meds - Elderly living in areas of low SES likely to receive opioid Rx #ACR21 @RheumNow #BeersCriteria https://t.co/fxBGVAtt1L

#ACR21 #Abstr1426 VEXAS is only recently described but a study in 83 patients showed importance of genotyping + clinical in predicting mortality: 💠p.Met41Val (OR: 2.6) 💠Transfusion dependent (4.5) 💠Ear chondritis protective (0.3) @RheumNow #ACRBest https://t.co/RQwONf2MJT https://t.co/VLWRGKWmQs

• Genotype and Transfusion Dependence Predicts Mortality in VEXAS Syndrome, a New…

The VEXAS story developing and becoming clearer... with high mortality genotype-phenotype linked genotype at risk for mortality (p.Met41Val) - smaller residual UBA1b expression - less RP - more fever wonderful from @maferradastrong #ACR21 ABST1426 @RheumNow @RP_Organization https://t.co/vELXprUrPh

Voclosporin for lupus nephritis maintained reductions in proteinuria. No change in eGFR at 30 months of treatment (AURORA 2 study) Abs#1425 #ACR21 @RheumNow https://t.co/1y9oSVXzD8

#ACR21 Abs#1427- Statin Use in RA ⭐️# needed to treat: 42 pts all-cause mortality ⭐️NNT 102 pts CVD events ⭐️# needed to harm: 127 pts T2DM (mild ⬆️ risk) ▶️Statin use: mortality benefit better than gen pop, CVD&DM similar effects to gen pop @Rheumnow https://t.co/m5bl9Ho163 https://t.co/hijxbcVBzA

• https://bit.ly/3bPbT7t